Amgen, Inc. (NASDAQ:AMGN) EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $176.83, for a total value of $269,665.75. Following the transaction, the executive vice president now directly owns 56,106 shares in the company, valued at approximately $9,921,223.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Amgen, Inc. (NASDAQ AMGN) traded down $0.57 during trading on Tuesday, hitting $176.26. The company’s stock had a trading volume of 2,193,736 shares, compared to its average volume of 3,205,624. Amgen, Inc. has a 12 month low of $145.12 and a 12 month high of $191.10. The company has a market capitalization of $127,331.98, a P/E ratio of 13.94, a P/E/G ratio of 2.54 and a beta of 1.36. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The company had revenue of $5.77 billion during the quarter, compared to the consensus estimate of $5.75 billion. During the same period in the prior year, the company earned $3.02 earnings per share. The company’s revenue for the quarter was down .7% compared to the same quarter last year. equities research analysts expect that Amgen, Inc. will post 12.66 EPS for the current fiscal year.

Amgen announced that its Board of Directors has initiated a stock repurchase program on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be issued a $1.32 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 3.00%. Amgen’s dividend payout ratio is 41.63%.

A number of research firms recently commented on AMGN. Oppenheimer reiterated a “buy” rating and issued a $203.00 price objective on shares of Amgen in a report on Friday, October 6th. Mizuho reiterated a “buy” rating and issued a $198.00 price objective on shares of Amgen in a report on Friday, October 6th. Cann reiterated a “buy” rating on shares of Amgen in a report on Monday, August 28th. Bank of America upped their price objective on Amgen to $210.00 and gave the company a “buy” rating in a report on Thursday, October 5th. Finally, Jefferies Group reiterated a “buy” rating and issued a $200.00 price objective on shares of Amgen in a report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. Amgen has a consensus rating of “Hold” and a consensus price target of $190.22.

Several institutional investors have recently made changes to their positions in the business. Financial Advisory Service Inc. grew its holdings in shares of Amgen by 0.3% during the second quarter. Financial Advisory Service Inc. now owns 1,974 shares of the medical research company’s stock worth $340,000 after buying an additional 5 shares in the last quarter. Jackson Grant Investment Advisers Inc. grew its holdings in shares of Amgen by 0.8% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after buying an additional 5 shares in the last quarter. Capital Advisors Ltd. LLC grew its holdings in shares of Amgen by 0.6% during the second quarter. Capital Advisors Ltd. LLC now owns 1,103 shares of the medical research company’s stock worth $190,000 after buying an additional 7 shares in the last quarter. Ballentine Partners LLC grew its holdings in shares of Amgen by 0.3% during the second quarter. Ballentine Partners LLC now owns 3,441 shares of the medical research company’s stock worth $620,000 after buying an additional 9 shares in the last quarter. Finally, Hudock Capital Group LLC grew its holdings in shares of Amgen by 0.5% during the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock worth $330,000 after buying an additional 10 shares in the last quarter. Institutional investors own 78.62% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Sean E. Harper Sells 1,525 Shares of Amgen, Inc. (AMGN) Stock” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/12/sean-e-harper-sells-1525-shares-of-amgen-inc-amgn-stock.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.